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ABSTRACT
The inhibition of the mechanistic target of rapamycin complex 1 (mTORC1) 
by chemical inhibitors, such as rapamycin, has demonstrated anti-cancer activity 
in preclinical and clinical trials. Their efficacy is, however, limited and tumors 
eventually relapse through resistance formation. In this study, using two different 
cancer mouse models, we identify tumor hypoxia as a novel mechanism of 
resistance of cancer cells against mTORC1 inhibitors. Indeed, we show that the 
activity of mTORC1 is mainly restricted to the non-hypoxic tumor compartment, as 
evidenced by a mutually exclusive staining pattern of the mTORC1 activity marker 
pS6 and the hypoxia marker pimonidazole. Consequently, whereas rapamycin 
reduces cancer cell proliferation in non-hypoxic regions, it has no effect in hypoxic 
areas, suggesting that cancer cells proliferate independently of mTORC1 under 
hypoxia. Targeting the hypoxic tumor compartment by knockdown of carbonic 
anhydrase IX (CAIX) using short hairpin RNA or by chemical inhibition of CAIX 
with acetazolamide potentiates the anti-cancer activity of rapamycin. Taken 
together, these data emphasize that hypoxia impairs the anti-cancer efficacy of 
rapalogs. Therapeutic strategies targeting the hypoxic tumor compartment, such 
as the inhibition of CAIX, potentiate the efficacy of rapamycin and warrant further 
clinical evaluation.
INTRODUCTION
Over the last decade, extensive research focused 
on targeting signaling pathways that are deregulated 
in cancer and promote tumor growth. In this context, 
blocking the mechanistic target of rapamycin (mTOR) 
has demonstrated clinical benefits in cancer patients that 
are however limited due to the development of resistance 
mechanisms [1-4]. Hence, it is important to identify 
these mechanisms in order to improve the efficacy of 
mTOR inhibitors. mTOR exerts its biological functions 
as a subunit of two different protein complexes; the 
mTOR complex 1 (mTORC1) and the mTOR complex 
2 (mTORC2) [5]. mTORC1 is activated by growth-
promoting stimuli such as growth factors or amino acids. 
In contrast, unfavorable growth conditions such as low 
energy levels or hypoxia lead to mTORC1 inactivation. 
Once activated, mTORC1 controls cell growth through 
various mechanisms including protein, lipid and 
nucleotide synthesis as well as inhibition of autophagy [5, 
6]. In the context of cancer, overactivation of mTORC1 
is frequently observed in human tumors caused either 
by activating mutations of upstream components of the 
mTOR signaling pathway or by mutations of mTOR itself 
[7, 8]. Accordingly, several preclinical and clinical studies 
have evaluated the anti-cancer efficacy of mTORC1 
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inhibition by the chemical inhibitor rapamycin and its 
analogs termed rapalogs. Following encouraging results 
in mouse models, the efficacy of rapalogs was however 
lower than expected in patients [3].
Regions of hypoxia are frequently present in 
tumors and profoundly influence the biology of cancer 
and its response to therapies [9, 10]. Classically, a high 
rate of cancer cell proliferation combined with structural 
abnormalities of tumor endothelial cells induces regions 
in tumors featuring low oxygen levels. Tumor cells are 
able to quickly adapt to this hypoxic microenvironment 
by inducing the transcriptional activity of hypoxia 
inducible factors [11]. Among the different proteins 
whose expressions are stimulated by hypoxia, emerging 
evidence point out the importance of the carbonic 
anhydrase IX (CAIX) enzyme in promoting cancer cell 
growth [12]. Indeed, blocking CAIX either by genetic 
manipulations or by using chemical inhibitors significantly 
reduces the growth of tumor xenografts in mice [13-15]. 
Moreover, targeting CAIX enhances the anti-cancer 
efficacy of anti-angiogenic therapies or radiotherapy [14, 
16]. Furthermore, expression of CAIX in human tumor 
samples is associated with tumor progression and poor 
prognosis [17, 18].
In this study, we found that mTORC1 activity was 
diminished in hypoxic tumor regions. Consequently, 
rapamycin failed to reduce cancer cell proliferation 
in these regions. We further observed that combining 
treatments that target components of the hypoxic tumor 
response, such as CAIX, potentiated the anti-cancer 
efficacy of rapamycin. Taken together, these results show 
that hypoxic cancer cells proliferate independently of 
mTORC1 and are hence intrinsically resistent to mTOR 
inhibitors. They further provide a rationale to combine 
CAIX and mTOR inhibitors in cancer therapy.
RESULTS
mTORC1 activity in cancer cells is reduced in 
hypoxic regions of the tumor
It was previously reported that hypoxia inhibits 
mTORC1 activity in vitro [19]. We therefore first 
hypothesized that mTORC1 function is mainly present 
in non-hypoxic areas of a tumor. To test this, human 
colorectal adenocarcinoma cell line HT29 xenografts 
were generated in nude and murine colon adenocarcinoma 
cell line MC-38 allografts in C57BL/6 mice. After tumor 
harvest, mTORC1 activity and hypoxia were detected 
using immunohistochemical staining for phospho-S6 
ribosomal protein (pS6) and pimonidazole respectively. 
In addition, proliferating cell nuclear antigen (PCNA) 
staining was applied to assess cancer cell proliferation. 
We found that pS6 and pimonidazole stainings negatively 
correlated, whereas PCNA staining revealed proliferation 
in both compartments (Figure 1A). Similarly, the staining 
of phospho-4E-BP1, another downstream target of 
mTORC1, was predominantly found in pimonidazole 
negative tumor areas (Supplementary Figure S1). This 
suggests that, in hypoxic zones, cancer cells proliferate 
despite the reduction of mTORC1 activity (Figure 1A 
and 1B). Proliferation rate was however significantly 
decreased in hypoxic compared to non-hypoxic regions 
(proliferation rate in hypoxic region: HT29 71.4 %, MC-
38 68.9 %; proliferation rate in non-hypoxic region: HT29 
85.7 %, MC-38 86.4 %) (Figure 1B).
Rapamycin selectively reduces proliferation of 
cancer cells in non-hypoxic zones of tumors
We next hypothesized that, since mTORC1 activity 
is reduced in hypoxic regions, blocking mTOR with 
rapamycin would not influence cancer cell proliferation 
in these regions. To test this, nude mice bearing HT29 
tumor xenografts or C57BL/6 mice bearing MC-38 
allografts were treated with rapamycin or vehicle as a 
control. We found that, whereas rapamycin significantly 
reduced tumor cell proliferation in non-hypoxic zones 
(HT29: vehicle 85.7 %, rapamycin 74.3 %; MC-38: 
vehicle 86.4 %, rapamycin 74.2 %), it had no effect on 
hypoxic areas (HT29: vehicle 71.4 %, rapamycin 73.6 
%; MC-38: vehicle 68.9 %, rapamycin 70.5 %) (Figure 
2A). In accordance with these in vivo results, we found 
no anti-proliferative effect of rapamycin on cancer cells 
cultured in hypoxic conditions (1 % oxygen) (Figure 2B). 
Interestingly, in vivo, rapamycin increased the hypoxic 
tumor compartment compared to controls in both HT29 
tumor xenografts (from 18.5 % to 37.6 %) and MC-
38 tumor allografts (from 14.0 % to 38.2 %) (Figure 
3A). Consistent with this, we observed that rapamycin 
increased the level of CAIX protein expression from 18.2 
% to 32.4 % in HT29 tumors and from 7.8 % to 22.8 % in 
MC-38 tumors. This increased expression of CAIX was 
associated with a reduction of CD31 positive tumor blood 
vessels (Figure 3A). Upregulation of CAIX levels in the 
treated xeno- and allografts was confirmed by qRT-PCR 
(Figure 3B).
The anti-cancer activity of rapamycin is 
increased in combination with acetazolamide
Since rapamycin treatment increases the expression of 
CAIX, and CAIX is known to promote cancer progression, 
we next asked whether blocking CAIX activity would 
improve the efficacy of rapamycin. To test this, we treated 
nude mice bearing HT29 tumor xenografts or C57BL/6 mice 
bearing MC-38 allografts with acetazolamide alone or in 
combination with rapamycin. Although acetazolamide is a 
non-specific inhibitor of carbonic anhydrase enzymes, we 
opted for it as it is a regularly used agent and well tolerated 
by patients [20]. We found that both acetazolamide and 
rapamycin alone reduced tumor growth. The effect was 
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Figure 1: mTORC1 activity is reduced in hypoxic regions of a tumor. A. Serial sections of HT29 tumor xenografts and MC-
38 tumor allografts were stained for pimonidazole, pS6 or PCNA. Arrows point to pimonidazole positive, pS6 negative regions. Scale 
bar, 200 μm. B. Percentage of PCNA positive cancer cells was counted in 10 representative pimonidazole positive and 10 representative 
pimonidazole negative zones of a 100 × 100 μm surface for three different HT29 and MC-38 tumors for a total of 30 pimonidazole positive 
and 30 pimonidazole negative zones for each cell line (1 pimonidazole positive and 1 pimonidazole negative area used for counting is 
highlighted by squares (white in pimonidazole staining and black in PCNA staining) under A and displayed under B). Bar charts represent 
mean, error bars represent SD. *** p<0.001, Student’s t-test. Representative image section below corresponding bar chart, scale bar, 100 
μm.
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Figure 2: Hypoxic tumor regions proliferate independently of mTORC1 and are resistant to rapamycin. A. Percentage 
of PCNA positive cancer cells was counted in 10 representative pimonidazole positive and pimonidazole negative zones of a 100 × 100 μm 
surface for three different HT29 and MC-38 tumors. Representative image section below corresponding bar chart, scale bar, 100 μm. B. 
MTS cell proliferation assay of HT29 cells cultured in hypoxia (O2 1 %) or non-hypoxia (O2 21 %) and treated with DMSO or rapamycin 
100 nM was performed after 48 and 96 hours. Bar charts represent mean, error bars represent SD. **** p<0.0001, *** p<0.001, ns=not 
significant, Student’s t-test.
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however significantly stronger when both agents were 
combined (Figure 4A and 4B). The effect was long-lasting as, 
after three months of treatment, HT29 tumor xenografts did 
still not exceed a size of 230 mm3 (Figure 4C). Histological 
analysis revealed that acetazolamide increased tumor necrosis 
(from 7.4 % to 53.8 % and from 7.8 % to 44.8 % in HT29 
and MC-38 tumors respectively) and the number of tumor 
blood vessels (increase by 78.4 % in HT29 and 93.3 % in 
MC-38 tumors) (Figure 5). Interestingly, acetazolamide 
reduced proliferation in hypoxic (from 71.4 % to 54.6 % 
and from 68.9 % to 54.5 % in HT29 and MC-38 tumors 
respectively) but not in non-hypoxic regions, whereas the 
opposite was observed with rapamycin. Combined treatment 
with rapamycin and acetazolamide produced antiproliferative 
effects in both the hypoxic and non-hypoxic area (Figure 
6A and 6B). Taken together, these data demonstrate that 
Figure 3: Rapamycin increases carbonic anhydrase IX expression, tumor hypoxia and tumor necrosis and decreases 
tumor vasculature. A. Percentage of tumor hypoxia (pimonidazole positive surface), tumor necrosis (light pink stained surface in H&E) 
and CAIX expression (CAIX positive surface) were compared for vehicle and rapamycin treated tumors of HT29 xenograft and MC-38 
allograft in 10 representative sections of 3368 × 2668 μm for three different tumors. Tumor vasculature was analyzed by counting CD31 
positive vessels in 10 representative sections of 200 × 200 μm for three different tumors. Scale bars, 200 μm. B. mRNA was extracted from 
5 tumors and tested for CAIX levels and GAPDH as a control by qRT- PCR. Bar charts represent mean, error bars represent SD. **** 
p<0.0001, Student’s t-test.
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combining acetazolamide with rapamycin exhibits stronger 
anti-cancer effects than either drug alone.
Targeting CAIX potentiates the anti-cancer 
efficacy of rapamycin
We next investigated whether among the different 
carbonic anhydrase enzymes, targeting specifically CAIX 
would potentiate the anti-cancer effect of rapamycin. To 
test this, we knocked down CAIX in HT29 cells (HT29 
shCAIX) by infecting HT29 cells with lentiviruses 
containing CAIX shRNA. Knockdown of CAIX was 
confirmed by qRT-PCR (Figure 7A) and by immunostaining 
of tumor xenografts (Figure 7E). HT29 shCAIX or control 
HT29 expressing a scramble shRNA were injected 
subcutaneously into nude mice, and tumor growth was 
monitored. We found that the growth of HT29 shCAIX 
tumor xenografts was reduced compared to control HT29 
Figure 4: Acetazolamide potentiates the anti-cancer efficacy of rapamycin. A. HT29 xenograft growth curves for treatments 
with vehicle, acetazolamide (40 mg/kg daily), rapamycin (3 mg/kg daily) or a combination of both. B. MC-38 allograft growth curves with 
treatments as under a. C. Long term effect of acetazolamide/rapamycin treatments on the growth of HT29 xenografts. Arrows denote the 
start of treatment at 25 mm3 graft volume. **** p<0.0001, *** p<0.001, n=5/group, Two-way ANOVA.
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Figure 5: Acetazolamide increases necrosis and tumor vasculature. Percentage of tumor hypoxia (pimonidazole positive 
surface), tumor necrosis (light pink stained surface in H&E) and CAIX expression (CAIX positive surface) were compared for vehicle, 
rapamycin, acetazolamide and combined treatment of HT29 xenograft and MC-38 allograft in 10 representative sections of 3368 × 2668 
μm for three different tumors. Tumor vasculature was analyzed by counting CD31 positive vessels in 10 representative sections of 200 × 
200 μm for three different tumors. Scale bars, 200 μm. Bar charts represent mean, error bars represent SD. **** p<0.0001, *** p<0.001, 
ns=not significant, One-way ANOVA.
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(Figure 7B). Rapamycin treatment further reduced the 
growth of HT29 shCAIX tumor xenografts. This growth 
reduction was also stronger compared to rapamycin treated 
control xenografts. The tumor size of shCAIX xenografts 
was still below 200 mm3 after a long term rapamycin 
treatment of 20 days (Figure 7c). CAIX knockdown reduced 
proliferation in the hypoxic but not the non-hypoxic tumor 
regions. A combined inhibition of mTORC1 and CAIX 
provoked antiproliferative effects in both the hypoxic 
and non-hypoxic area (Figure 7d). Furthermore, CAIX 
knockdown decreased tumor hypoxia and tumor necrosis, 
but increased CD31 positive tumor vasculature (Figure 7e). 
Taken together, these results emphasize that an inhibition of 
CAIX potentiates the efficacy of rapamycin.
DISCUSSION
Targeting mTOR is a promising approach in cancer 
therapy. However, in the course of time, cancers adapt to 
mTOR inhibition and develop resistance mechanisms that 
are responsible for the limited efficacy of mTOR inhibitors 
[2]. To date, most identified resistance mechanisms are the 
consequence of an abrogation of negative feedback loops 
following mTORC1 inhibition [21]. In this study, we show 
Figure 6: CAIX inhibition by acetazolamide has an anti-proliferative effect on hypoxic tumor regions. A. B. Percentage 
of PCNA positive cancer cells was counted in 10 representative pimonidazole positive and pimonidazole negative zones of a 100 × 100 
μm surface for three different HT29 (A) and MC-38 (B) tumors respectively. Bar charts represent mean, error bars represent SD. **** 
p<0.0001, *** p<0.001, ns=not significant, Student’s t-test. Representative image section below corresponding bar chart, scale bar, 100 μm.
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Figure 7: CAIX knockdown exhibits an anti-proliferative effect on hypoxic tumor regions and potentiates anti-cancer 
efficacy of rapamycin. A. CAIX knockdown in HT29 cells was confirmed by qRT-PCR. **** p<0.0001, Student’s t-test. B. HT29 
control and HT29 shCAIX xenograft growth curves for treatments with vehicle or rapamycin (3 mg/kg daily). C. Long term effect of 
rapamycin treatment in HT29 shCAIX xenografts. Arrows denote the start of rapamycin treatment at 25 mm3 graft volume. **** p<0.0001, 
n=5/group, Two-way ANOVA. D. Percentage of PCNA positive cancer cells was counted in 10 representative pimonidazole positive and 
pimonidazole negative zones of a 100 × 100 μm surface for three different HT29 control or HT29 shCAIX tumors. Bar charts represent 
mean, error bars represent SD. **** p<0.0001, *** p<0.001, ns=not significant, Student’s t-test. Representative image section below 
corresponding bar chart, scale bar, 100 μm. E. Percentage of tumor hypoxia (pimonidazole positive surface), tumor necrosis (light pink 
stained surface in H&E) and CAIX expression (CAIX positive surface) were compared for control and CAIX knockdown HT29 xenograft 
with vehicle or rapamycin treatment in 10 representative sections of 3368 × 2668 μm for three different tumors. Tumor vasculature was 
analyzed by counting CD31 positive vessels in 10 representative sections of 200 × 200 μm for three different tumors. Scale bars, 200 μm. 
Bar charts represent mean, error bars represent SD. **** p<0.0001, ** p<0.01, * p<0.05, One-way ANOVA.
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that the hypoxic microenvironment of a tumor is resistant 
to mTOR inhibitors, and we propose that targeting the 
hypoxic region of a tumor is an effective approach to 
enhance their anti-tumor efficacy.
Most tumors are characterized by regions of 
hypoxia that contribute to chemo- and radioresistance 
[9]. Our findings show that hypoxia also contributes 
to resistance to mTOR inhibitors. Indeed, we outline 
that mTORC1 activity is not present in hypoxic regions 
of a tumor as evidenced by a mutually exclusive 
staining pattern of pimonidazole and pS6 (Figure 
1A). Consistent with this observation, it was reported 
that mTORC1 activity negatively correlated with 
HIF-1α expression in renal cancer xenografts [22]. 
Furthermore, we observe that rapamycin reduces 
cancer cell proliferation in non-hypoxic but not in 
hypoxic regions of a tumor (Figure 2A). This further 
supports our hypothesis that hypoxic cancer cells 
proliferate independently of mTORC1. Consistent with 
our observation that rapamycin exerts a tumor region 
selective anti-proliferative effect, it was reported that, 
whereas rapamycin decreases proliferation in the outer 
well vascularized part of tumors, it promotes cancer cell 
proliferation in hypovacular areas of tumors [23].
Another explanation for the loss of antiproliferative 
activity of rapamycin in hypoxic tumor regions is a 
reduced access of rapamycin to hypoxic areas. Indeed, 
rapamycin is well characterized for its anti-angiogenic 
properties [24, 25]. Consistent with this, we found that 
rapamycin decreased the number of blood vessels and 
increased tumor hypoxia which could secondarily lead to 
reduced rapamycin delivery to hypoxic tumor regions.
Adaptation of cancer cells to hypoxia involves 
the expression of many genes that are under the control 
of the transcription factor HIF-1 [9, 26]. Interestingly, 
several studies have demonstrated that HIF-1 expression 
is positively regulated by mTORC1, which would argue 
for a control of hypoxic gene activation by mTORC1 [27-
29]. The role of mTORC1 in regulating hypoxia-induced 
HIF-1 expression seems however complex and might 
depend on the level of hypoxia. Actually, whereas rapalogs 
were shown to partially reduce the level of HIF-1 induced 
by mild hypoxia (3 % O2), this effect was abrogated in 
conditions of severe hypoxia (0.3 % O2)[22]. Consistent 
with this, we demonstrate that rapamycin increases the 
expression of CAIX which is under the control of HIF-
1 (Figure 3). This further suggests that HIF-1-mediated 
hypoxic gene activation is not controlled by mTORC1 in 
the hypoxic tumor microenvironment.
Among the various proteins that are controlled by 
HIF-1, mounting evidence has outlined the importance 
of CAIX in cancer biology. In different experimental 
settings, CAIX knockdown reduced the growth rate of 
tumor xenografts, and conversely, overexpression of 
CAIX increased tumor growth [13-15]. Similarly, we 
see that CAIX knockdown slows the progression of 
tumor xenografts (Figure 7B and 7C). We further show 
that cancer cell proliferation in hypoxic zones is reduced 
following knockdown of CAIX (Figure 7D), highlighting 
the importance of CAIX to maintain favorable growth 
conditions in a hypoxic environment. Similarly, in vitro, 
it was demonstrated that CAIX expression was associated 
with proliferation in hypoxic areas of cancer cell spheroids 
[14]. Therefore, CAIX actively participates in tumor 
growth, and accordingly, selective inhibitors of CAIX are 
currently tested in clinical trials [30, 31].
The primary function of CAIX is the hydration of 
carbon dioxide to bicarbonate and proton, maintaining 
an alkaline intracellular pH and promoting an acidic 
extracellular space [30, 32]. Our observation therefore 
suggests that increasing the tumor pH via inhibition of 
CAIX might potentiate the efficacy of mTOR inhibitors. 
Of note, acidic extracellular pH inhibits mTORC1 
function [33, 34]. Consequently, in addition to hypoxia, 
acidic tumor pH might further downregulate mTORC1 
activity and promote an mTORC1-independent cancer 
cell proliferation. Besides CAIX, several other proteins 
are implicated in the regulation of tumor pH, including 
bicarbonate transporters, proton pump, Na+/H+ exchanger 
1 or monocarboxylate transporter [35, 36]. Future studies 
will characterize whether modifying the functions of 
these proteins might influence the anti-cancer efficacy of 
mTORC1 inhibitors.
A combination of rapamycin with CAIX inhibitors 
is further justified by the observation that rapamycin 
treatment increases the extent of hypoxia in tumors 
which is associated with an increased expression of 
CAIX (Figure 3). This observation relies mostly on the 
reduction of the number of tumor blood vessels induced by 
rapamycin. Therefore, targeting CAIX is of importance in 
combination with treatments that increase tumor hypoxia 
such as anti-angiogenesis therapies. A reinforcement 
of the anti-tumoral activity of the anti-VEGF antibody 
bevacizumab by an inhibition of CAIX further supports 
this hypothesis [14].
Our study further underlines the benefit of 
therapeutic approaches that target the hypoxic tumor 
response in combination with anti-angiogenic agents. 
Consistent with our findings, such an approach has 
shown promising results in other pre-clinical models 
[37]. For example, targeting HIF1α increases the efficacy 
of bevacizumab in neuroblastoma xenografts [38]. A 
similar effect has also been reported when bevacizumab is 
combined with acetazolamide [14] [39]. More importantly, 
such strategies are also tested in clinical trials [37].
Combining inhibitors of the hypoxic tumor response 
with rapamycin could be particularly beneficial compared 
to their combinations with other anti-angiogenic drugs. 
Indeed the importance of mTORC1 in tumors is not 
restricted to tumor vessels; mTORC1 also affects cancer 
cells and cells present in the tumor microenvironment. 
Hence, blocking mTORC1 can lead to unexpected effects 
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due to the variety and complexity of cellular responses 
induced by mTORC1 inhibition. For example it was 
demonstrated that in a mouse model of K-Ras-induced 
pancreatic tumors, mTORC1 has opposing effect on tumor 
cell proliferation in nutrient-rich versus nutrient-depleted 
conditions. Whereas it blocks tumor cell proliferation in 
vascular tumor areas, it increases tumor cell proliferation 
in hypovascular, nutrient depleted regions, resulting 
overall in tumor growth [23]. This further outlines that 
targeting the hypoxic tumor regions can potentiate the 
efficacy of mTORC1 inhibitors.
Preclinical studies have underlined a role of 
acetazolamide in restraining cellular processes involved 
in tumor progression. For instance, renal cancer cell 
invasiveness and survival is diminished by acetazolamide 
in vitro [40, 41]. In addition, acetazolamide has shown 
anti-tumor properties in murine models [14, 42, 43]. Our 
data further demonstrate that acetazolamide-induced 
tumor growth inhibition is associated with reduced cancer 
cell proliferation in hypoxic zones (Figure 6A and 6B), 
which is in accordance with what we observe following 
selective knockdown of CAIX (Figure 7D). However, 
whereas CAIX knockdown significantly reduces tumor 
necrosis (Figure 7E), treatment with acetazolamide 
results in increased necrosis (Figure 5). The non-selective 
property of acetazolamide for the inhibition of carbonic 
anhydrase isoforms might explain this discrepancy.
We found that acetazolamide treatment or CAIX 
knockdown in cancer cells significantly increased the 
number of blood vessels in tumors. The molecular 
mechanisms underlying this effect remain however 
uncharacterized. Acidity is known to reduce endothelial 
cell proliferation and migration as well as endothelial 
cell sprouting [44, 45]. Hence, increasing intratumoral 
pH following the inhibition of carbonic anhydrase 
enzymes could favor tumor angiogenesis. A direct 
effect of acetazolamide on endothelial cells has also to 
be considered. Indeed, carbonic anhydrase II has been 
detected on tumor endothelial cells, and its inhibition 
could affect endothelial cell functions that are relevant to 
angiogenesis [46]. Clearly, additional investigations are 
needed to fully characterize the effect of targeting carbonic 
anhydrase enzymes on tumor endothelium.
The mechanisms responsible for the anti-cancer 
activity of rapamycin are complex and not restricted to 
its effect on tumor and endothelial cells [2]. Consistent 
with this, the antiproliferative effect of rapamycin on 
cancer cells that we describe here is small and cannot 
solely account for the anti-cancer activity of rapamycin 
in our study as well as in patients. Recent studies have 
demonstrated the complex role of mTORC1 in the immune 
system [47]. Although classically rapamycin is used as an 
immunosuppressive drug, several evidence point out that 
in distinct conditions rapamycin favors CD8+ memory 
response and hence mediates an immunostimulatory 
response [48-50]. Thus, besides the antiproliferative 
effects of rapamycin, several other aspects contribute 
to the anti-cancer activity of rapamycin and need to be 
fully identified. Our experimental set-up did not allow 
to investigate the tumor immune response. Hence future 
experiments will determine whether inhibition of the 
hypoxic tumor response in combination with rapamycin 
positively influences tumor immune response.
Tumors are characterized by genetic and epigenetic 
alterations that play a fundamental role in malignant 
transformation. However, genetic and epigenetic 
alterations display a spatial and temporal heterogeneity and 
vary in consequence of anti-cancer treatments [51]. This 
tumor heterogeneity may account for the limited efficacy 
of targeting therapies. Our findings further emphasize that 
the tumor microenvironment affects signaling pathways 
that participate in tumor growth, adding another level of 
complexity to the molecular heterogeneity of tumors.
In summary, our study shows that mTORC1 activity 
is reduced in hypoxic tumor regions which consequently 
resist to mTORC1 inhibitors. Targeting the hypoxic 
microenvironment represents a novel therapeutic strategy 
to potentiate the efficacy of mTORC1 inhibitors.
MATERIALS AND METHODS
Cell culture, reagents, antibodies
Human colorectal adenocarcinoma cell line HT29 
were purchased from American Type Culture Collection and 
murine colon adenocarcinoma cell line MC-38 were kindly 
provided by Dr. Jeffrey Schlom (National Cancer Institute, 
NIH) [52]. Cell lines were cultured in Dulbecco’s Modified 
Eagle’s Medium - high glucose (DMEM) (Sigma-Aldrich) 
supplemented with 10 % FBS and 1 % streptomycin/
penicillin. Rapamycin was from LC Laboratories. 
Acetazolamide was from Sigma-Aldrich. For cell culture, 
rapamycin was dissolved in dimethyl sulfoxide (DMSO). 
For mouse models, rapamycin and acetazolamide were 
dissolved in DMSO at the below-mentioned dosage and 
diluted 1:5 in PBS-Tween-PEG (89.6 % phosphate-buffered 
saline (PBS), 5.2 % Tween 20, 5.2 % poly(ethylene glycol)). 
Solid pimonidazole HCl as part of the HydroxyprobeTM-1 Kit 
was from hpi Hydroxyprobe Inc. For immunohistochemical 
staining, the following primary antibodies and concentrations 
were used: Anti-phospho S6 ribosomal protein antibody 
(1:100) (M3500; Spring Bioscience Corp.), anti-CD31/
PECAM-1 antibody (1:50) (RB-10333; ThermoFisher 
Scientific), anti-carbonic anhydrase IX antibody (1:100) 
(NB100-417; Novus Biologicals), anti-PCNA antibody 
(1:50) (ab2426; Abcam) and anti-phospho-4E-BP1 antibody 
(1:100) (2855; Cell Signaling Technology).
Proliferation assay
HT29 cells were plated on 96 well plates (Costar) 
at 5’000 cells per well, cultured in DMEM in hypoxia 
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O2 1 % or non-hypoxia O2 21 % and treated with DMSO 
or 100 nM rapamycin for 48 and 96 hours. Cellular 
proliferation was monitored after 48 and 96 hours with 
CellTiter 96 AQueous One Solution Cell Proliferation 
Assay (MTS) (Promega Corporation) by following the 
manufacturer’s instructions. Absorbance at 492 nm was 
measured 30 minutes after compound administration. 
Experiment was performed in quadruplicates and 
repeated three times.
Stable transfection
To knockdown CAIX in HT29 cells, we used 
lentivirus produced by the lenti-vpak packaging kit from 
OriGene following the manufacturer’s instructions and 
containing the CAIX gene-specific shRNA expression 
vector (TL314250B) or a negative control non-effective 
HuSH 29-mer scrambled shRNA cassette (TR30021) 
in pGFP-C-shLenti plasmid. Cells were grown under 
selective pressure (puromycin 10 μg/ml), and the 
knockdown efficiency was tested by qRT-PCR.
qRT-PCR
RNA extraction was performed using RNeasy 
Mini Kit from Qiagen by following the manufacturer’s 
instructions. We used 500 ng of RNA for reverse 
transcription with SuperScript II Reverse Transcriptase 
from ThermoFisher Scientific. The resulting cDNA was 
used for qRT-PCR (Rotor-Gene Q from Qiagen). qRT-
PCR were set up in triplicates with KAPA SYBR FAST 
qPCR Kit Master Mix Universal KK4602 from Kapa 
Biosystems. Relative gene expression and fold changes 
were determined using the 2-ΔΔCT method using GAPDH 
as an internal control [53]. Primer sequences were: human 
CAIX forward GGG TGT CAT CTG GAC TGT GTT, 
human CAIX reverse CTT CTG TGC TGC CTT CTC 
ATC, human GAPDH forward CCA TGG GGA AGG 
TGA AGG TC, human GAPDH reverse ACG TAC TCA 
GCG CCA GCA TC, mouse CAIX forward GCT GTC 
CCA TTT GGA AGA AA, mouse CAIX reverse GGA 
AGG AAG CCT CAA TCG TT, mouse GAPDH forward 
AAG AGG GAT GCT GCC CTT A, mouse GAPDH 
reverse TTG TCT ACG GGA CGA GGA AA.
Immunohistochemistry
Xeno- and allografts were fixed in formaline 4 
% overnight, dehydrated with ethanol and paraffin-
embedded. Sections of 3 μm were obtained using 
MICROM HS355S microtome, and tissue sections 
were mounted on Superfrost Plus slides. Slides were 
then deparaffinized and rehydrated with xylol and 
alcohol. After antigen retrieval (citrate pH 6.0 or TRIS/
EDTA pH 9.0), sections were immunostained using 
above-mentioned primary antibodies for 60 minutes 
incubation time and subsequently incubated with Dako 
EnVision HRP secondary rabbit or mouse antibody 
for 30 minutes. One section from each xenograft and 
allograft tumor and three tumors for each condition 
were analyzed for each staining. Carl Zeiss Axioscope, 
AxioCam MRc and AxioVision 40V 4.6.3.0 software 
from Carl Zeiss Imaging Solutions GmbH were used for 
microscopy, imaging acquisition and image processing. 
Histology analysis was performed by two researchers 
blinded to groupings. Percentage of tumor hypoxia 
(pimonidazole positive surface), tumor necrosis (light 
pink stained surface in H&E) and CAIX expression 
(CAIX positive surface) were measured quantitatively 
using ImageJ 1.46r Threshold Colour Plugin analysis 
by analyzing 10 representative images of 3368 × 2668 
μm for each condition in three different tumors. Tumor 
vasculature was analyzed by counting CD31 positive 
vessels in 10 representative sections of 200 × 200 μm 
for three different tumors. PCNA positive and PCNA 
negative cancer cells were counted in 10 representative 
pimonidazole positive and pimonidazole negative 
vital tumor zones of a 100 x 100 μm surface for three 
different HT29 and MC-38 tumors. Proliferation rate 
was calculated by dividing the number of PCNA positive 
cancer cells by the number of PCNA positive and PCNA 
negative cancer cells.
Mouse models
Animal experiments were in accordance with 
the Swiss federal animal regulations and approved by 
the local veterinary office. Female nude and C57BL/6 
eight-week old mice were purchased from Janvier Labs. 
HT29 cells (3 x 106) and MC-38 (1 x 106) cells were 
injected subcutaneously into the right flank. Once the 
tumor xeno-/allografts reached a mean size of 25 mm3, 
mice were randomized into different groups (n=5/group; 
groups “vehicle” – “acetazolamide” – “rapamycin” 
– “acetazolamide and rapamycin”) and treated daily 
with rapamycin (3 mg/kg/day, intraperitoneally), 
acetazolamide (40 mg/kg/day, intraperitoneally), a 
combination of both or vehicle only. Tumor volumes 
were measured daily using a caliper and calculated with 
the formula V = A * B * C * π / 6 where A is the length, 
B the width and C the height of the tumor. Animals were 
sacrificed once the biggest tumor of vehicle treated mice 
reached the size of 1000 mm3 (defined as interruption 
criterion according to veterinary recommendations). 
Pimonidazole HCl 15 mg/ml in NaCl 0.9 % was injected 
intraperitoneally at a dosage of 60 mg/kg, 60 minutes 
before tissue harvest. Tumors were excised and samples 
processed for immunohistochemical analysis.
Statistics
Statistical analysis including Student’s t-test, One-
way ANOVA and Two-way ANOVA were carried out as 
appropriate using GraphPad Prism version 6.05.
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